361 related articles for article (PubMed ID: 19940847)
1. Delays in new drug applications in Japan and industrial R&D strategies.
Hirai Y; Kinoshita H; Kusama M; Yasuda K; Sugiyama Y; Ono S
Clin Pharmacol Ther; 2010 Feb; 87(2):212-8. PubMed ID: 19940847
[TBL] [Abstract][Full Text] [Related]
2. Approval of new biopharmaceuticals 1999-2006: comparison of the US, EU and Japan situations.
Tsuji K; Tsutani K
Eur J Pharm Biopharm; 2008 Mar; 68(3):496-502. PubMed ID: 17884403
[TBL] [Abstract][Full Text] [Related]
3. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
Pflieger M; Bertram D
Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
[TBL] [Abstract][Full Text] [Related]
4. Drug marketing exclusivity under United States and European Union law.
Junod V
Food Drug Law J; 2004; 59(4):479-518. PubMed ID: 15875347
[No Abstract] [Full Text] [Related]
5. International Conference on Harmonisation; Guidance on S9 Nonclincal Evaluation for Anticancer Pharmaceuticals; availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2010 Mar; 75(44):10487-8. PubMed ID: 20383918
[TBL] [Abstract][Full Text] [Related]
6. International Conference on Harmonisation; guidance on M4 common technical document; availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2001 Oct; 66(200):52634-7. PubMed ID: 12358037
[TBL] [Abstract][Full Text] [Related]
7. [Contact and dialogue between drug companies and the global regulatory authorities throughout research and development phase].
Kock M; Thomsen MK
Ugeskr Laeger; 2003 Apr; 165(16):1649-52. PubMed ID: 12756820
[TBL] [Abstract][Full Text] [Related]
8. Significant differences in drug lag in clinical development among various strategies used for regulatory submissions in Japan.
Ueno T; Asahina Y; Tanaka A; Yamada H; Nakamura M; Uyama Y
Clin Pharmacol Ther; 2014 May; 95(5):533-41. PubMed ID: 24213186
[TBL] [Abstract][Full Text] [Related]
9. International Conference on Harmonisation; Guidance on E2F Development Safety Update Report; availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2011 Aug; 76(163):52667-8. PubMed ID: 21894658
[TBL] [Abstract][Full Text] [Related]
10. Industry perspectives on ICH guidelines.
Rockhold FW
Stat Med; 2002 Oct; 21(19):2949-57. PubMed ID: 12325111
[TBL] [Abstract][Full Text] [Related]
11. New drug approval times and clinical evidence in Japan.
Ono S; Yoshioka C; Asaka O; Tamura K; Shibata T; Saito K
Contemp Clin Trials; 2005 Dec; 26(6):660-72. PubMed ID: 16122988
[TBL] [Abstract][Full Text] [Related]
12. Characteriation of clinical data packages using foreign data in new drug applications in Japan.
Tanaka M; Nagata T
Clin Pharmacol Ther; 2008 Sep; 84(3):340-6. PubMed ID: 17786162
[TBL] [Abstract][Full Text] [Related]
13. The "Drug export lag" and the Drug Export Amendments Act of 1986: an evaluation.
Pathak DS; Hakim Z; Kucukarslan S
Clin Ther; 1994; 16(2):283-305; discussion 271-2. PubMed ID: 8062323
[TBL] [Abstract][Full Text] [Related]
14. International Conference on Harmonisation; draft guidance on E2F Development Safety Update Report; availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2008 Aug; 73(151):45462-3. PubMed ID: 18949880
[TBL] [Abstract][Full Text] [Related]
15. International Conference on Harmonisation; guidance on Addendum to E2C Clinical Safety Data Management: Periodic Safety Update Reports for Marketed Drugs; availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2004 Feb; 69(24):5551-2. PubMed ID: 14968802
[TBL] [Abstract][Full Text] [Related]
16. International Conference on Harmonisation: guidance on Q1D bracketing and matrixing designs for stability testing of new drug substances and products; availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2003 Jan; 68(11):2339-40. PubMed ID: 12532979
[TBL] [Abstract][Full Text] [Related]
17. Economic advantage of pharmacogenomics - clinical trials with genetic information.
Ohashi W; Mizushima H; Tanaka H
Stud Health Technol Inform; 2008; 136():585-90. PubMed ID: 18487794
[TBL] [Abstract][Full Text] [Related]
18. International Conference on Harmonisation; choice of control group and related issues in clinical trials; availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2001 May; 66(93):24390-1. PubMed ID: 12356096
[TBL] [Abstract][Full Text] [Related]
19. [Our policy and future tasks related to ICH in anti-cancer drug development--a discussion from the viewpoint of an enterprise].
Ekimoto H
Gan To Kagaku Ryoho; 1997 Jan; 24(2):229-37. PubMed ID: 9030236
[TBL] [Abstract][Full Text] [Related]
20. International Conference on Harmonisation; Guidance on E16 Biomarkers Related to Drug or Biotechnology Product Development: Context, Structure, and Format of Qualification Submissions; availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2011 Aug; 76(155):49773-4. PubMed ID: 21834216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
